Kite Pharma, Inc. (KITE) Shares Sold by DSAM Partners London Ltd
DSAM Partners London Ltd lowered its position in shares of Kite Pharma, Inc. (NASDAQ:KITE) by 4.1% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 92,970 shares of the biopharmaceutical company’s stock after selling 3,990 shares during the period. Kite Pharma makes up about 1.7% of DSAM Partners London Ltd’s portfolio, making the stock its 21st largest position. DSAM Partners London Ltd owned about 0.16% of Kite Pharma worth $9,638,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in the stock. BlackRock Inc. boosted its position in shares of Kite Pharma by 106,272.1% in the first quarter. BlackRock Inc. now owns 3,621,971 shares of the biopharmaceutical company’s stock worth $284,287,000 after buying an additional 3,618,566 shares during the last quarter. Point72 Asset Management L.P. boosted its position in shares of Kite Pharma by 235.0% in the first quarter. Point72 Asset Management L.P. now owns 819,900 shares of the biopharmaceutical company’s stock worth $64,354,000 after buying an additional 575,178 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Kite Pharma by 16.1% in the first quarter. Vanguard Group Inc. now owns 3,661,547 shares of the biopharmaceutical company’s stock worth $287,395,000 after buying an additional 507,289 shares during the last quarter. Columbia Wanger Asset Management LLC purchased a new position in shares of Kite Pharma during the first quarter worth approximately $35,452,000. Finally, Menora Mivtachim Holdings LTD. boosted its position in shares of Kite Pharma by 13.9% in the first quarter. Menora Mivtachim Holdings LTD. now owns 1,433,899 shares of the biopharmaceutical company’s stock worth $112,547,000 after buying an additional 175,000 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.
Shares of Kite Pharma, Inc. (NASDAQ:KITE) opened at 178.05 on Tuesday. The firm’s market cap is $10.18 billion. Kite Pharma, Inc. has a 1-year low of $39.82 and a 1-year high of $179.69. The firm’s 50-day moving average price is $115.89 and its 200 day moving average price is $87.67. Kite Pharma also saw some unusual options trading activity on Monday. Stock investors purchased 23,676 put options on the company. This is an increase of approximately 1,264% compared to the typical volume of 1,736 put options.
Kite Pharma (NASDAQ:KITE) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.97) by $0.03. The company had revenue of $10.10 million during the quarter, compared to analyst estimates of $9.59 million. Kite Pharma had a negative net margin of 1,117.44% and a negative return on equity of 59.56%. The company’s revenue for the quarter was up 110.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.91) EPS. On average, equities research analysts forecast that Kite Pharma, Inc. will post ($7.96) EPS for the current fiscal year.
WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/kite-pharma-inc-kite-shares-sold-by-dsam-partners-london-ltd/1529432.html.
A number of equities analysts have commented on KITE shares. Goldman Sachs Group, Inc. (The) increased their target price on Kite Pharma from $85.00 to $89.00 and gave the company a “buy” rating in a report on Tuesday, May 9th. Canaccord Genuity set a $115.00 target price on Kite Pharma and gave the company a “buy” rating in a report on Monday, July 10th. Wedbush cut Kite Pharma from a “neutral” rating to an “underperform” rating and reduced their target price for the company from $60.00 to $54.00 in a report on Tuesday, May 9th. Jefferies Group LLC set a $101.00 target price on Kite Pharma and gave the company a “buy” rating in a report on Friday, May 19th. Finally, Vetr raised Kite Pharma from a “strong sell” rating to a “strong-buy” rating and set a $116.82 target price for the company in a report on Monday, July 17th. Fifteen investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Kite Pharma currently has an average rating of “Hold” and a consensus price target of $88.93.
In other news, COO Cynthia M. Butitta sold 15,000 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $120.72, for a total transaction of $1,810,800.00. Following the transaction, the chief operating officer now owns 132,795 shares in the company, valued at approximately $16,031,012.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Helen Susan Kim sold 79,949 shares of the firm’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $119.56, for a total transaction of $9,558,702.44. Following the transaction, the executive vice president now owns 98,613 shares in the company, valued at approximately $11,790,170.28. The disclosure for this sale can be found here. Insiders have sold a total of 266,299 shares of company stock worth $28,364,633 in the last 90 days. 14.00% of the stock is owned by insiders.
About Kite Pharma
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
Want to see what other hedge funds are holding KITE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kite Pharma, Inc. (NASDAQ:KITE).
Receive News & Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.